Subcutaneous Immunoglobulin for Primary and Secondary Immunodeficiencies: an Evidence-Based Review

被引：0
|
作者：
Jenny Lingman-Framme
Anders Fasth
机构：
[1] Halland Hospital,Department of Pediatrics
[2] University of Gothenburg,Department of Pediatrics
来源：
Drugs | 2013年 / 73卷
关键词：
Hematopoietic Stem Cell Transplantation; Hyaluronidase; Child Health Questionnaire; Secondary Immunodeficiency; Immunoglobulin Substitution;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1307 / 1319
页数：12
相关论文
共 50 条
  • [1] Subcutaneous Immunoglobulin for Primary and Secondary Immunodeficiencies: an Evidence-Based Review
    Lingman-Framme, Jenny
    Fasth, Anders
    DRUGS, 2013, 73 (12) : 1307 - 1319
  • [2] Subcutaneous immunoglobulin replacement in primary immunodeficiencies
    Berger, M
    CLINICAL IMMUNOLOGY, 2004, 112 (01) : 1 - 7
  • [3] Subcutaneous Immunoglobulin as Replacement Therapy of Children with Primary Immunodeficiencies
    Uglova, T.
    Aleshkevich, S.
    JOURNAL OF CLINICAL IMMUNOLOGY, 2014, 34 : S308 - S308
  • [4] Subcutaneous Immunoglobulin Replacement Therapy in Infants and Children with Primary Immunodeficiencies
    Church, J. A.
    Howard, V.
    Sleasman, J. W.
    Borte, M.
    Berger, M.
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2011, 127 (02) : AB213 - AB213
  • [5] Implications to payers of switch from hospital-based intravenous immunoglobulin to home-based subcutaneous immunoglobulin therapy in patients with primary and secondary immunodeficiencies in Canada
    Gerth, William C.
    Betschel, Stephen D.
    Zbrozek, Arthur S.
    ALLERGY ASTHMA AND CLINICAL IMMUNOLOGY, 2014, 10
  • [6] Implications to payers of switch from hospital-based intravenous immunoglobulin to home-based subcutaneous immunoglobulin therapy in patients with primary and secondary immunodeficiencies in Canada
    William C Gerth
    Stephen D Betschel
    Arthur S Zbrozek
    Allergy, Asthma & Clinical Immunology, 10
  • [7] Implications to payers of switch from hospital-based intravenous immunoglobulin (IVIg) to home-based subcutaneous immunoglobulin (SCIg) therapy in patients with primary immunodeficiencies (PID) and secondary immunodeficiencies (SID) in Canada
    William C Gerth
    Stephen D Betschel
    Arthur S Zbrozek
    Allergy, Asthma & Clinical Immunology, 10 (Suppl 1)
  • [8] Subcutaneous immunoglobulin replacement in patients with primary immunodeficiencies (PID) - Portuguese experience
    Faria, E.
    Lopes-Silva, S.
    Marques, L.
    Guedes, M.
    Goncalo-Marques, J.
    CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2008, 154 : 103 - 104
  • [9] Transitioning subcutaneous immunoglobulin 20% therapies in patients with primary and secondary immunodeficiencies: Canadian real-world study
    Keith, Paul K.
    Cowan, Juthaporn
    Kanani, Amin
    Kim, Harold
    Lacuesta, Gina
    Lee, Jason K.
    Chen, Jie
    Park, Michelle
    Gladiator, Andre
    ALLERGY ASTHMA AND CLINICAL IMMUNOLOGY, 2022, 18 (01):
  • [10] Correction: Transitioning subcutaneous immunoglobulin 20% therapies in patients with primary and secondary immunodeficiencies: Canadian real‑world study
    Paul K. Keith
    Juthaporn Cowan
    Amin Kanani
    Harold Kim
    Gina Lacuesta
    Jason K. Lee
    Jie Chen
    Michelle Park
    André Gladiator
    Allergy, Asthma & Clinical Immunology, 19
12345